Spring Creek Capital’s LumiraDx Limited Warrant LMDXW Stock Holding History

Spring Creek Capital’s Portfolio LMDXW Stock Details LMDXW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-125,000	Closed	-$101K	–	301
2022 Q1	$101K	Hold	125,000	–	–	﹤0.01%	496
2021 Q4	$179K	Hold	125,000	–	–	0.01%	419
2021 Q3	$158K	Buy	+125,000	New	+$145K	0.01%	354

Other funds holding LMDXW

CVS Health Woonsocket, Rhode Island $212M AUM 19.39% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

Spring Creek Capital's LMDXW Position: Q2 2022 in Review

Spring Creek Capital sold out of LumiraDx Limited Warrant (LMDXW) in Q2 2022, closing a stake of 125,000 shares — an estimated $101K sold.

Spring Creek Capital first reported a position in LMDXW in Q3 2021 and held it in 3 quarters. The position peaked at $179K in Q4 2021. 21 funds tracked by Wall St. Rank hold LMDXW as of Q2 2022.

Spring Creek Capital reported no remaining LumiraDx Limited Warrant position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 125,000 LumiraDx Limited Warrant shares in Q2 2022, an estimated $101K.
Spring Creek Capital first reported a position in LumiraDx Limited Warrant in Q3 2021 and held it in 3 quarters.
Spring Creek Capital's LumiraDx Limited Warrant position peaked at $179K in Q4 2021.
21 funds tracked by Wall St. Rank held LumiraDx Limited Warrant as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.